IQV — IQVIA Holdings, Inc.

Is IQV overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

IQVIA Holdings, Inc. (IQV) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $249.28. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

IQVIA is well positioned as a diversified CRO and health‑data leader benefiting from durable outsourcing trends, increasing demand for biologics/advanced therapies, and recurring revenue from analytics platforms. Near‑term performance will track pharma R&D spending cadence and program timelines; margin expansion is achievable via operational leverage and productized data offerings, while execution and regulatory/data risks require monitoring. Given steady market conditions and sector tailwinds, the company has a constructive growth runway with scenarios dependent on macro/R&D trends and competitive dynamics.

Key factors

  • Leading global CRO and health‑data platform with diversified revenue streams across clinical research, commercial analytics, and technology-enabled services
  • Structural demand tailwinds from biologics, gene therapies, and growing outsourcing of R&D and specialized analytical testing (positive readthrough from GLP-1/biologics & CRO/CDMO theme)
  • Recurring, high‑quality revenue from data and software platforms that improve revenue visibility and margins over time
  • Strong cash flow generation and history of targeted M&A to extend capabilities and addressable market
  • Operational leverage opportunity as AI and process automation raise efficiency across clinical trial execution and real‑world evidence services

Risks

  • A macro slowdown or tighter pharma R&D budgets could delay programs and reduce near‑term CRO demand
  • Intense competition from other large CROs and specialized CDMOs could pressure pricing and share in select service lines
  • Regulatory, data privacy, or FTC enforcement actions affecting digital health/data monetization could increase compliance costs and limit commercial use cases
  • Execution and integration risk from acquisitions or large program ramp‑ups that could compress margins if not managed
  • Currency exposure and client concentration risk in certain geographies or therapeutic areas

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for IQV — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.